A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Non-clinical Pharmacokinetic Study
Tien-Tzu Tai, Tzung-Ju Wu, Huey-Dong Wu, Yi-Chen Tsai, Hui-Ting Wang, An-Min Wang, Sheue-Fang Shih, Yee-Chun Chen
This study evaluates a liposomal HCQ formulation delivered via inhalation in rats, showing higher lung exposure and longer half-life compared to IV administration, with reduced systemic toxicity.
bioRxiv · Jul 9, 2020Pharmacology & Toxicology